Non-Hodgkin's Lymphoma
Conditions
Keywords
NHL, Rituxan, Lymphoma, CD20-positive, B-Cell, APM4083g
Brief summary
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has progressed following previous rituximab therapy.
Interventions
DRUGPRO95780
Intravenous repeating dose
DRUGrituximab
Intravenous repeating dose
Sponsors
Genentech, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed Informed Consent Form * Age ≥ 18 years * Diagnosis of follicular, CD20-positive B-cell NHL * Progression of disease after an objective response or stable disease lasting \> 6 months following completion of the most recent rituximab-containing regimen * Measurable disease * Life expectancy of \> 3 months
Exclusion criteria
* Grade 3b follicular lymphoma (according to the WHO classification) or histologic transformation from follicular lymphoma to aggressive lymphoma * Prior radiotherapy to a lesion(s) that will be used to assess response unless that lesion(s) shows clear evidence of lymphoma progression at baseline * Radiotherapy to a peripheral lesion within 14 days prior to Cycle 1, Day 1 or radiotherapy to a thoracic, abdominal, or pelvic field within 28 days prior to Cycle 1, Day 1 * Concurrent systemic corticosteroid therapy * Other invasive malignancies within 3 years prior to first study drug administration except for adequately treated basal or squamous cell skin cancer, in situ carcinoma of the cervix, in situ breast cancer, in situ prostate cancer, limited-stage bladder cancer, or other cancers from which the patient has been disease-free for at least 3 years. * History or evidence on physical examination of central nervous system (CNS) disease * Prior treatment with agonistic DR4 or DR5 antibodies or Apo2L/TRAIL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response, as determined by independent review facility | 8 months |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, as determined by independent review facility | up to 12 months |
| Duration of objective response, as determined by independent review facility | up to 10.3 months |
| Overall survival | Up to 18.5 months |
| Objective response, as determined by the investigator | Up to 8 months |
| Progression-free survival, as determined by the investigator | Up to 18.5 months |
| Duration of objective response, as determined by the investigator | Up to 14.1 months |
Outcome results
None listed